RASTETTER WILLIAM H 4

What Happened
William H. Rastetter, a director of Fate Therapeutics (FATE), exercised or converted derivatives on May 5, 2026 to acquire a total of 50,000 shares. The filing shows 25,000 shares exercised at $1.69 per share (cash paid $42,250) and an additional 25,000 shares reported at $0.00 (listed as a derivative acquisition). These transactions are acquisitions (exercise/conversion of options), not sales.

Key Details

• Transaction date: 2026-05-05; Form 4 filed 2026-05-06 (filed the next day; appears timely).
• Entries: 25,000 shares @ $1.69 (Acquired — $42,250); 25,000 shares @ $0.00 (Acquired — derivative).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: Some shares are owned of record by The Rastetter Family Trust (William H. Rastetter and Marisa Gard Rastetter are co‑trustees).
  • F2: Some shares are owned of record by The Investment Trust (William H. Rastetter is sole trustee/owner).
  • F3: The options subject to the exercise vested and became exercisable as of the 2017 Annual Meeting.
• No sale or immediate disposition of the shares is indicated in this filing.

Context
This Form 4 reports option exercises/conversions (transaction code M). The filing does not indicate a cashless sale or any disposition — it simply shows acquisition of shares via exercise/conversion. Footnotes show record ownership through family/investment trusts, which can affect where shares are held on public records but do not by themselves indicate motivation. The filing appears timely (filed the next day).